Analysis
The article highlights the strategic shift of pharmaceutical giants towards in-house AI development to address the burgeoning data volume in drug discovery. This internal focus suggests a desire for greater control over intellectual property and a more tailored approach to addressing specific research challenges, potentially leading to faster and more efficient development cycles.
Key Takeaways
- •AstraZeneca is investing in in-house AI capabilities.
- •The focus is on integrating AI into research and clinical workflows.
- •The goal is to accelerate oncology drug development.
Reference / Citation
View Original"The challenge is no longer whether AI can help, but how tightly it needs to be built into research and clinical work to improve decisions around trials and treatment."